clinical trial · NCT04436640
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
UCB Biopharma SRL·phase3·active not recruiting·n = 508
Axial SpondyloarthritisAnkylosing Spondylitisr-axSpaNr-axSpaBimekizumab
brief summary
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
started
Jun 16, 2020
primary completion
Aug 7, 2026
completion
Aug 7, 2026
last updated
May 8, 2026
official title
A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol